Geneos Wealth Management’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-1,000
Closed -$42K 2589
2019
Q4
$42K Hold
1,000
﹤0.01% 1346
2019
Q3
$32K Hold
1,000
﹤0.01% 1396
2019
Q2
$36K Hold
1,000
﹤0.01% 1355
2019
Q1
$36K Hold
1,000
﹤0.01% 1308
2018
Q4
$27K Sell
1,000
-1,150
-53% -$38.1K ﹤0.01% 1375
2018
Q3
$84K Buy
2,150
+1,250
+139% +$47.4K 0.01% 953
2018
Q2
$33K Hold
900
﹤0.01% 1242
2018
Q1
$30K Hold
900
﹤0.01% 1227
2017
Q4
$29K Buy
900
+100
+13% +$3.13K ﹤0.01% 1249
2017
Q3
$24K Buy
+800
New +$23.5K ﹤0.01% 1257
2016
Q4
Sell
-500
Closed -$13K 2084
2016
Q3
$13K Hold
500
﹤0.01% 1284
2016
Q2
$11K Buy
+500
New +$11.9K ﹤0.01% 1300

Other funds holding SBIO

Geneos Wealth Management's SBIO Position: Q1 2020 in Review

Geneos Wealth Management sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q1 2020, closing a stake of 1,000 shares — an estimated $42K sold.

Geneos Wealth Management first reported a position in SBIO in Q2 2016 and held it in 12 quarters. The position peaked at $84K in Q3 2018. 47 funds tracked by Wall St. Rank hold SBIO as of Q1 2020.

  • Geneos Wealth Management reported no remaining ALPS Medical Breakthroughs ETF position as of Q1 2020 after selling out during the quarter.
  • Geneos Wealth Management sold 1,000 ALPS Medical Breakthroughs ETF shares in Q1 2020, an estimated $42K.
  • Geneos Wealth Management first reported a position in ALPS Medical Breakthroughs ETF in Q2 2016 and held it in 12 quarters.
  • Geneos Wealth Management's ALPS Medical Breakthroughs ETF position peaked at $84K in Q3 2018.
  • 47 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q1 2020.

Based on Geneos Wealth Management's 13F filing for Q1 2020, filed 7 Sep 2021.